by Clinical Neuropsychologist | Tuesday, September 24, 2024 | Dementia
Abstract INTRODUCTION We investigated the prevalence of amyloid beta (Aβ) positivity (+) and cognitive trajectories in Koreans and non-Hispanic Whites (NHWs). METHODS We included 5121 Koreans from multiple centers across South Korea and 929 NHWs from the...
by Clinical Neuropsychologist | Monday, September 23, 2024 | Dementia
Abstract INTRODUCTION We examined the burden of Alzheimer’s disease and other dementias (ADOD) and attributable factors at the national and provincial levels in China. METHODS Using the Global Burden of Diseases Study 2021, we estimated incidence, prevalence,...
by Clinical Neuropsychologist | Monday, September 23, 2024 | Dementia
Abstract INTRODUCTION Subjective cognitive decline (SCD) may be an early marker of Alzheimer’s disease (AD) pathology. Until recently, it was impossible to measure biomarkers specific for α-synuclein pathology; therefore, its association with subjective reports...
by Clinical Neuropsychologist | Monday, September 23, 2024 | Dementia
Abstract Early diagnosis is crucial to treatment success. This is especially relevant for Alzheimer’s disease (AD), with its protracted preclinical phase. Most health care systems do not have the resources to conduct large-scale AD screenings in middle-aged...
by Clinical Neuropsychologist | Monday, September 23, 2024 | Dementia
Abstract INTRODUCTION The microglial receptor triggering receptor expressed on myeloid cells 2 (TREM2) is a major risk factor for Alzheimer’s disease (AD). Experimentally, Trem2 deficiency affects parenchymal amyloid beta (Aβ) deposition. However, the role of...
